Key result
Longer therapeutic anticoagulation linked to ~14% lower in-hospital mortality per day in COVID-19.
Why the study?
Does systemic treatment-dose anticoagulation reduce in-hospital mortality in patients hospitalized with COVID-19?
Cohort (n=2,773)
Does systemic treatment-dose anticoagulation reduce in-hospital mortality in patients hospitalized with COVID-19?
Answers are grounded in this paper and cite their sources.
Systemic treatment-dose anticoagulation may be associated with improved survival in patients hospitalized with COVID-19, particularly those requiring mechanical ventilation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Paranjpe et al. (2020) conducted a cohort in COVID-19 (n=2,773). Systemic treatment-dose anticoagulation vs. No treatment-dose anticoagulation was evaluated on In-hospital mortality (adjusted HR 0.86 per day, 95% CI 0.82-0.89, p=<0.001). Longer duration of systemic treatment-dose anticoagulation was associated with a reduced risk of in-hospital mortality among patients hospitalized with COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: